These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22076476)

  • 1. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
    Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
    Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.
    Dizdar O; Ozçakar L; Malas FU; Harputluoglu H; Bulut N; Aksoy S; Ozisik Y; Altundag K
    J Clin Oncol; 2009 Oct; 27(30):4955-60. PubMed ID: 19752344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
    Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
    PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
    J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
    J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
    Chim K; Xie SX; Stricker CT; Li QS; Gross R; Farrar JT; DeMichele A; Mao JJ
    BMC Cancer; 2013 Sep; 13():401. PubMed ID: 24004677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
    Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
    Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
    Henry NL; Giles JT; Ang D; Mohan M; Dadabhoy D; Robarge J; Hayden J; Lemler S; Shahverdi K; Powers P; Li L; Flockhart D; Stearns V; Hayes DF; Storniolo AM; Clauw DJ
    Breast Cancer Res Treat; 2008 Sep; 111(2):365-72. PubMed ID: 17922185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
    Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
    Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
    Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
    Morales L; Pans S; Verschueren K; Van Calster B; Paridaens R; Westhovens R; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    J Clin Oncol; 2008 Jul; 26(19):3147-52. PubMed ID: 18474874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
    J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
    Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.